Idm Pharma Inc

Idm Pharma — Investor Presentation (January 2006)

30 slides from Idm Pharma's investor presentation, Jan 6, 2006

  1. Slide 1: DRAFT Confidential January 2006

    DRAFT CONFIDENTIAL January, 2006

  2. Slide 2: Safe Harbor Statement

    This presentation includes forward-looking statements that reflect management's current views of future events such as statements about the expected timing of milestone events, the potential therapeutic benefits of and expected commercial plans for our product candidates, and our strategic goals. Ac

  3. Slide 3: Mission

    Mission IDM is focused on the development of innovative products that activate the immune system to treat cancer. Goal: To cure while caring for quality of life

  4. Slide 4: Highlights

    Highlights Broad clinical development pipeline: Lead product completed Phase III 4 additional products in clinical development Product and equity partnership with Sanofi-Aventis R&D engine: Approval of one product sets the foundation for next product Strong intellectual property position Headquarter

  5. Slide 5: Fully operational facilities in U.S. and Europe

    Fully operational facilities in U.S. and Europe California France Regulatory certified facilities in Irvine and Paris

  6. Slide 6: Corporate partners

    Corporate partners sanofi aventis

  7. Slide 7: Product candidates

    Product candidates Destroy cancer cells by activating innate immunity Prevent tumor recurrence by triggering a specific adaptive immune response Two product lines in oncology with the goals to:

  8. Slide 8: Product candidate pipeline

    Product candidate pipeline (2) Sanofi-Aventis has option for joint development and sole commercialization Candidate Indication Phase I Phase II Phase III Marketing Rights (2) Ph III trial completed Junovan(tm) Osteosarcoma IDM Ph II/III Bexidem(r) Bladder cancer IDM Ph II Uvidem(r) Melanoma Ph I/II

  9. Slide 9: First line of products to destroy cancer cells

    First line of products to destroy cancer cells (2) Ph III trial completed Junovan (tm) Osteosarcoma IDM (1) Ph II/III Bexidem (tm) Bladder cancer IDM Candidate Indication Phase I Phase II Phase III Marketing Rights Ph II Uvidem(tm) Melanoma Ph I/II Collidem(tm) Colorectal cancer IDM Ph I/II EP-2101

  10. Slide 10: Macrophage ability to kill a tumor cell

    Macrophage ability to kill a tumor cell 1 hr 30 min macrophage tumor cell 6 hr tumor cell debris

  11. Slide 11: Junovan: Completed Phase III in osteosarcoma

    Junovan: Completed Phase III in osteosarcoma Fully synthetic compound Targeting osteosarcoma, bone cancer in adolescents Orphan drug status in EU & U.S.

  12. Slide 12: Junovan: Phase II results in relapsed osteosarcoma

    Junovan (MTP-PE) as single agent after surgical resection of lung metastases Limited side effects Junovan: Phase II results in relapsed osteosarcoma with lung metastases 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Disease-Free Survival Months Klei

  13. Slide 13: Junovan: Phase III osteosarcoma results

    Junovan: Phase III osteosarcoma results Overall Survival Years Proportion Surviving 0 1 2 3 4 5 6 0.0 0.2 0.4 0.6 0.8 1.0 - - Junovan + Junovan Disease-Free Survival Years Proportion Surviving relapse free 0 1 2 3 4 5 6 0.0 0.2 0.4 0.6 0.8 1.0 - - Junovan + Junovan In 664 patients with non-metastati

  14. Slide 14: Junovan: Product status

    Junovan: Product status Expect to File NDA by mid-2006, launch anticipated in 2007 Exclusive worldwide sales and marketing rights outside of UK Annual worldwide market potential ~$100 million Orphan drug designation provides 7 year marketing exclusivity in the U.S. and 10 years in Europe upon approv

  15. Slide 15: Bexidem

    Thiounn N. et al, Journal of Urology 168, 2373-76, 2002 Bexidem Product containing activated macrophages Targeting bladder cancer Addresses unmet medical needs Tumor removal, local chemo and BCG therapy of limited benefit Phase I/II clinical trial completed Tumor occurrences for 17 patients decrease

  16. Slide 16: Bexidem: Product status

    Bexidem: Product status Ongoing Phase II/III clinical trial in Europe FDA Special Protocol Assessment expected in 2006 Interim data analysis expected early 2007 Exclusive worldwide sales and marketing rights Opportunity to partner with large pharma More than 60,000 new cases of Bladder cancer per ye

  17. Slide 17: Second line of products to prevent tumor recurrence

    Second line of products to prevent tumor recurrence (1) Sanofi-Aventis has option for joint development and sole commercialization (1) Ph III trial completed Junovan Osteosarcoma IDM Ph II/III Bexidem (tm) Bladder cancer IDM Candidate Indication Phase I Phase II Phase III Marketing Rights Ph II Uvid

  18. Slide 18: IDM Cell Drug therapy - an efficient process

    IDM Cell Drug therapy - an efficient process Outpatient apheresis Apheresis product Ship Elutriation Purified dendritic cells or MAK 20 doses from one apheresis Ship Outpatient treatment Culture with cytokines 7 Days Proprietary IDM Process Wash & concentrate and freeze cells

  19. Slide 19: Uvidem: Partnered with Sanofi-Aventis

    Uvidem: Partnered with Sanofi-Aventis Cell Drug: dendritic cells loaded with melanoma cell lysates Targeting melanoma - the most deadly form of skin cancer Addresses unmet medical need Phase I/II trial completed 15 patients with metastatic melanoma stage III and IV Product well-tolerated with no maj

  20. Slide 20: Uvidem: Product status

    Uvidem: Product status Phase II data in late stage patients presented at ASCO, May 2005 Phase II trial in earlier stage patients on going in US Phase II combination trial in EU started in 2005 Phase III in US and EU expected to start in 2007 Close to 60,000 new melanoma diagnosed in the U.S. per yea

  21. Slide 21: Key partnership with Sanofi-Aventis

    Key partnership with Sanofi-Aventis Sanofi-Aventis has an option for exclusive worldwide rights on selected products IDM receives milestones payments and reimbursement of clinical expenses Manufacturing at IDM and transfer price including royalties First product selected: Uvidem, in Phase II for tre

  22. Slide 22: Collidem and EP-2101

    Collidem: Dendritic cells + peptides Targeting colorectal cancer - the third most common cause of death from cancer in the U.S. Phase I/II clinical trial in the U.S. to evaluate immune and clinical responses in addition to safety in patients with metastatic colorectal cancer Enrollment of patients c

  23. Slide 23: Multi-epitope product pipeline

    Multi-epitope product pipeline Colorectal (Collidem) Ovarian Prostate Breast Lung (EP2101)

  24. Slide 24: Financial data

    Financial data Nine Months Ended Statement of Operations September 30, 2005 (Thousands except loss per share) Total revenues $ 5,226 Loss from operations (30,742) Net loss (29,506) Loss per share $3.19 Balance Sheet As of September 30, 2005 (Thousands) Cash and cash equivalents $21,252 Total assets

  25. Slide 25: Management team

    Management team Herve Duchesne de Lamotte, MBA VP, Finance Europe MIT, AT Kearney Guy-Charles Faneau de la Horie, DVM, MBA VP, General Manager, Europe Biogen, Schering Plough, Baxter Robert J. De Vaere VP, CFO Vista Medical Technologies Bonnie Mills, PhD VP, Clinical Operations and General Manager,

  26. Slide 26: Experienced non executive board members

    Experienced non executive board members Robert Beck, MD VP of Fox Chase Cancer Center Jean Deleage, PhD Managing general partner, Alta Partners Don Drakeman, JD, PhD CEO of Medarex Inc. Mike Grey CEO of SGX Pharmaceuticals, Inc. Sylvie Gregoire, Pharma D Former VP regulatory of Biogen Inc. and CEO o

  27. Slide 27: Ownership

    Ownership Directors and Officers Other Medarex Sanofi-Aventis split 3 59.6 19.9 15 (Direct ownership only, excludes beneficial ownership) (Including 19% held by Alta Partners, Atlas, Apax, CLAL, Schroders and Sofinnova combined)

  28. Slide 28: 2006 expected milestones

    Junovan - fast track designation in Osteosarcoma Junovan - FDA/EMEA NDA filing Bexidem - Special Protocol Assessment for Phase II/III Uvidem - complete enrollment of melanoma phase II trials Collidem - Phase I/II trial results in colorectal cancer EP-2101 - complete phase II trial enrollment in lung

  29. Slide 29: Summary

    Summary Lung EP2101 Candidate Indication Phase I Phase II Phase III Ph III trial completed Junovan(tm) Osteosarcoma Ph II/III Bexidem (tm) Bladder cancer Ph II Uvidem(tm) Melanoma Ph I/II Collidem (tm) Colorectal cancer Ph I/II EP-2101 NSC Lung Cancer

  30. Slide 30: DRAFT www.idm-pharma.com

    DRAFT CONFIDENTIAL www.idm-pharma.com NASDAQ: IDMI

IDM Pharma — Investor Presentation (January 2006) on 6ix